Clinical Lab Services – Internationally Standardized Testing – LabPMM2021-09-01T16:08:08+00:00
CLINICAL LAB SERVICES

Internationally Standardized Test Services

CLINICAL LAB SERVICES

Internationally
Standardized Test Services

LabPMM offers Clinical Services with Global Reach

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offers internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

LabPMM offers Clinical Services with Global Reach

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offers internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

NGS Cancer Panels

NGS Cancer Panels

Cytogenetic identification of chromosome abnormalities has become essential for the clinical management of patients with leukemia and is currently used to help categorize patients into risk groups.

Cytogenetic identification of chromosome abnormalities has become essential for the clinical management of patients with leukemia and is currently used to help categorize patients into risk groups.

Multiparametric Flow Cytometry Panels

LabPMM’s Multiparametric Flow Cytometry (MFC) Panels complement NGS testing –
streamlining clinical trials for accurate results comparisons.

Multiparametric Flow Cytometry Panels

LabPMM’s Multiparametric Flow Cytometry (MFC) Panels complement NGS testing –
streamlining clinical trials for accurate results comparisons.

Hematolymphoid Screening Panel – MFC

AML MRD Assay – MFC

FUTURE DEVELOPMENT SERVICES

Multiparametric Flow Cytometry Panels

Multiple Myeloma Minimum Residual Disease by Multiparametric Flow Cytometry (MM MRD by MFC)

(CD38, CD138, CD27, CD56, CD28, CD45, CD19, CD20, CD117, CD81, cytoplasmic Kappa, and cytoplasmic Lambda)

Chronic Lymphocytic Leukemia (CLL) Minimum Residual Disease by Multiparametric Flow Cytometry (CLL MRD by MFC)

(CD3, CD5, CD19, CD22, CD24, CD43, CD45, CD79b, CD81, and CD160)

B-Acute lymphoblastic leukemia (B-ALL) Minimal Residual Disease Panel by Multiparametric Flow Cytometry (B-ALL MRD by MFC)

(CD123, CD45, CD19, CD34, CD38, CD10, CD22, CD58, CD66C, CD9, CD13, CD33, and CD20)

Custom Immunophenotyping panels for drug development

Markers based on client’s need

NGS MRD Services

MRD NGS Tests

LabPMM’s MRD services are NGS-based tests that can be used to detect clonal gene rearrangements identified at diagnosis within virtually all of the antigen receptor loci for both B- and T-cells.

LabPMM’s MRD services are NGS-based tests that can be used to detect clonal gene rearrangements identified at diagnosis within virtually all of the antigen receptor loci for both B- and T-cells.

LabPMM’s Multiparametric Flow Cytometry (MFC) Panels complement NGS testing –
streamlining clinical trials for accurate results comparisons.

Targeted Gene Services

Targeted Gene Services

FLT3 and NPM1 tests are offered to detect targeted mutations.

FLT3 and NPM1 tests are offered to detect targeted mutations.

Clonality NGS Services

Clonality NGS Services

The unique process of genetic rearrangements in the immunoglobulin (Ig) and T-cell receptor (TCR) gene loci during immune cell development and maturation generates a vast pool of genetically distinct cells.

The unique process of genetic rearrangements in the immunoglobulin (Ig) and T-cell receptor (TCR) gene loci during immune cell development and maturation generates a vast pool of genetically distinct cells.

Companion Diagnostic (CDx) Services

Companion Diagnostic (CDx) Services

The fms related tyrosine kinase 3 (FLT3) is one of the most commonly mutated genes in acute myeloid leukemia (AML), occurring in approximately 30% of patients at the time of diagnosis1. Although generally associated with normal cytogenetics where patients have standard risk of relapse, FLT3 mutations have also been identified in sub-groups of patients with chromosomal abnormalities that are associated with high risk of disease relapse2-3.

The fms related tyrosine kinase 3 (FLT3) is one of the most commonly mutated genes in acute myeloid leukemia (AML), occurring in approximately 30% of patients at the time of diagnosis1. Although generally associated with normal cytogenetics where patients have standard risk of relapse, FLT3 mutations have also been identified in sub-groups of patients with chromosomal abnormalities that are associated with high risk of disease relapse2-3.

Custom Assay Development Services

Custom Assay Development Services

In response to the FDA announcing its intention to dramatically expand its regulatory oversight of laboratory developed tests (LDTs), Invivoscribe is partnering with laboratories worldwide to help facilitate the conversion of LDTs into FDA-cleared assays, as we know the barriers to bringing new assays online are often the availability of resources and the cost of validation.

In response to the FDA announcing its intention to dramatically expand its regulatory oversight of laboratory developed tests (LDTs), Invivoscribe is partnering with laboratories worldwide to help facilitate the conversion of LDTs into FDA-cleared assays, as we know the barriers to bringing new assays online are often the availability of resources and the cost of validation.